Hudson Edge Investment Partners Inc. Purchases 13,394 Shares of Bristol Myers Squibb Company $BMY

Hudson Edge Investment Partners Inc. grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 10.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,968 shares of the biopharmaceutical company’s stock after purchasing an additional 13,394 shares during the period. Hudson Edge Investment Partners Inc.’s holdings in Bristol Myers Squibb were worth $6,538,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Exchange Capital Management Inc. boosted its position in Bristol Myers Squibb by 0.4% during the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after acquiring an additional 220 shares during the last quarter. CVA Family Office LLC increased its position in shares of Bristol Myers Squibb by 2.6% during the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 223 shares in the last quarter. Parsons Capital Management Inc. RI raised its stake in shares of Bristol Myers Squibb by 0.3% in the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock worth $3,615,000 after purchasing an additional 224 shares during the last quarter. Richwood Investment Advisors LLC lifted its stake in Bristol Myers Squibb by 1.7% during the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock valued at $616,000 after acquiring an additional 225 shares in the last quarter. Finally, Mccarter Private Wealth Services LLC boosted its stake in shares of Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 235 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY to a Buy, saying the stock’s risk/reward is skewed to the upside; the call likely attracted buyers and underpins bullish sentiment. Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock
• Positive Sentiment: BMY announced a partnership with Microsoft to apply AI for earlier lung-cancer detection — a strategic move that can expand diagnostic reach, support earlier use of BMY oncology assets, and generates positive sentiment around future revenue/health‑tech synergies. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: The UK is set to adopt a new use for Opdivo in early-stage lung cancer, increasing commercial upside and supporting BMY’s oncology revenue profile. New Opdivo use in early lung cancer set for adoption in UK
• Positive Sentiment: Street bulls (Leerink) highlight ample pipeline optionality for 2026, reinforcing longer‑term growth expectations and supporting multiple expansion. Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026
• Neutral Sentiment: Zacks issued small, mixed EPS estimate tweaks (minor upward and downward adjustments across quarters/years) — not a major directional catalyst but worth monitoring for guidance revisions. Zacks Research EPS estimate updates for BMY
• Neutral Sentiment: Ongoing clinical updates (KarXT long‑term urological safety study) and routine mentions on shows like CNBC’s Fast Money keep BMY in the newsflow; these items sustain attention but are incremental. KarXT safety study update
• Negative Sentiment: Separately, a recent ~3% pullback and commentary about institutional owners potentially taking action highlight near‑term selling pressure and remind investors of volatility risk. Bristol-Myers Squibb Company’s (NYSE:BMY) recent 3.0% pullback adds to one-year year losses, institutional owners may take drastic measures

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BMY shares. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Guggenheim reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Finally, HSBC reiterated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $54.42 on Thursday. The business’s fifty day moving average is $52.28 and its 200 day moving average is $48.29. The company has a market capitalization of $110.78 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter last year, the business posted $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 85.14%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.